AstraZeneca shots 74pct effective in trial

Updated September 29 2021 - 9:20pm, first published 9:16pm
AstraZeneca's overall efficacy in the study was lower than the 79 per cent figure reported in March.

AstraZeneca's COVID-19 vaccine has demonstrated 74 per cent efficacy at preventing symptomatic disease, a figure that increased to 83.5 per cent in people aged 65 and older, according to long-awaited results of the company's US clinical trial.



Get the latest Batemans Bay news in your inbox

Sign up for our newsletter to stay up to date.

We care about the protection of your data. Read our Privacy Policy.